Study comparing new targeted drug plus chemo vs osimertinib for lung cancer with brain tumors
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-squamous non-small cell lung cancer that has spread to the brain.
- Your cancer cells have an EGFR mutation (either exon 19 deletion or L858R).
- You have not had any prior cancer treatment for advanced or metastatic lung cancer.
- You are at least 18 years old and in generally good health (able to take care of yourself).
- You have at least one brain tumor and one tumor outside the brain that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a higher dose of a newer targeted pill (furmonertinib) to a standard targeted pill (osimertinib) for advanced lung cancer with an EGFR mutation that has spread to the brain. The goal is to see if the higher dose works better at controlling the cancer in the brain.
This study tests two doses of furmonertinib (a targeted pill) combined with chemotherapy for people with a specific EGFR gene change in lung cancer that has spread to the brain. It aims to see if the higher dose works better while keeping side effects manageable.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial studies two targeted therapy drugs, furmonertinib and anlotinib, given together as a pill treatment. It is for people with a specific genetic change (EGFR mutation) in lung cancer that has spread to the brain.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
Hear when a new NSCLC Patients With Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.